lemaitre vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. the company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. the company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. the company is listed on nasdaq.
Company profile
Ticker
LMAT
Exchange
Website
CEO
George LeMaitre
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
LeMaitre Vascular GmbH • LeMaitre Acquisition LLC • LeMaitre Vascular SAS • LeMaitre Vascular Spain, S.L. • LeMaitre Vascular S.r.l. • Vascutech Acquisition LLC • LeMaitre Vascular ULC • LeMaitre Vascular Switzerland GmbH • LeMaitre Vascular Pty Ltd • LeMaitre Medical Technology (Shanghai) Co., Ltd ...
LMAT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
LeMaitre Q4 2023 Financial Results
27 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
LeMaitre Q3 2023 Financial Results
1 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
LeMaitre Q2 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 23
SD
Conflict minerals disclosure
31 May 23
Transcripts
LMAT
Earnings call transcript
2023 Q4
27 Feb 24
LMAT
Earnings call transcript
2023 Q3
1 Nov 23
LMAT
Earnings call transcript
2023 Q2
1 Aug 23
LMAT
Earnings call transcript
2023 Q1
2 May 23
LMAT
Earnings call transcript
2022 Q4
23 Feb 23
LMAT
Earnings call transcript
2022 Q3
28 Oct 22
LMAT
Earnings call transcript
2022 Q2
30 Jul 22
LMAT
Earnings call transcript
2022 Q1
30 Apr 22
LMAT
Earnings call transcript
2021 Q4
25 Feb 22
LMAT
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.05 mm | 18.05 mm | 18.05 mm | 18.05 mm | 18.05 mm | 18.05 mm |
Cash burn (monthly) | 479.00 k | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 3.25 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 14.80 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 30.9 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
86.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 220 |
Opened positions | 31 |
Closed positions | 23 |
Increased positions | 94 |
Reduced positions | 69 |
13F shares | Current |
---|---|
Total value | 1.05 tn |
Total shares | 19.48 mm |
Total puts | 400.00 |
Total calls | 12.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 3.27 mm | $178.33 bn |
Conestoga Capital Advisors | 1.92 mm | $104.47 bn |
Vanguard | 1.51 mm | $82.30 bn |
Copeland Capital Management | 1.23 mm | $67.08 bn |
Geneva Capital Management | 906.63 k | $49.39 bn |
Ranger Investment Management | 898.82 k | $48.97 bn |
STT State Street | 781.95 k | $42.60 bn |
Dimensional Fund Advisors | 669.98 k | $36.50 bn |
Congress Asset Management | 508.38 k | $27.70 bn |
Geode Capital Management | 437.93 k | $23.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Martha Shadan | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 1.235 | 0.00 | 1.235 |
28 Mar 24 | Martha Shadan | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.964 | 0.00 | 4.962 |
28 Mar 24 | Martha Shadan | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.964 | 0.00 | 5.951 |
28 Mar 24 | Roush John A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 1.235 | 0.00 | 1.235 |
28 Mar 24 | Roush John A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.964 | 0.00 | 4.962 |
28 Mar 24 | Roush John A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.964 | 0.00 | 5.951 |
28 Mar 24 | Roush John A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.476 | 0.00 | 6.914 |
28 Mar 24 | Ross Bridget A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 1.235 | 0.00 | 1.235 |
28 Mar 24 | Ross Bridget A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.964 | 0.00 | 4.962 |
28 Mar 24 | Ross Bridget A | Dividend Equivalent Rights Common Stock | Grant | Acquire A | No | No | 0 | 0.964 | 0.00 | 5.951 |
News
Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know
28 Feb 24
Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $69
28 Feb 24
Recap: LeMaitre Vascular Q4 Earnings
27 Feb 24
LeMaitre Vascular Q4 2023 GAAP EPS $0.38 Beats $0.36 Estimate, Sales $48.88M Miss $49.02M Estimate
27 Feb 24
Earnings Scheduled For February 27, 2024
27 Feb 24
Press releases
LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024
19 Apr 24
LeMaitre to Present at the 23rd Annual Needham Virtual Healthcare Conference
26 Mar 24
LeMaitre to Participate at Upcoming Investor Conferences in March
1 Mar 24
LeMaitre Q4 2023 Financial Results
27 Feb 24
LeMaitre Will Announce Fourth Quarter 2023 Earnings Results February 27, 2024
13 Feb 24